Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis

Basit Öğe Kaydı
dc.contributor.authorAleagha, Omid Emami
dc.contributor.authorOltulu, Pembe
dc.contributor.authorSadeghi, Masoud
dc.date.accessioned2024-02-23T14:40:54Z
dc.date.available2024-02-23T14:40:54Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractAim of the study: We reported the association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma (HCC) susceptibility in a meta-analysis. Material and methods: The studies were retrieved by searching the search terms in Scopus, PubMed, Web of Science, and Cochrane Library databases until June 2020. The analyses were done by RevMan 5.3 software using odds ratios (ORs) and 95% confidence intervals (Cis) and the analysis of publication bias and sensitivity analyses were performed by CMA 2.0 software. Results: Searching through the databases, 316 records were retrieved and finally 13 studies were analyzed in the present meta-analysis. For the rs1800797 polymorphism, there was an elevated risk of AA genotype (OR = 2.68, p = 0.03) in HCC patients compared to healthy controls. Also, there was an elevated risk of M (OR = 3.06, p = 0.04) and GA (OR = 2.61, p = 0.005) genotypes in HCC patients compared to liver cirrhosis patients. For rs2069837 polymorphism, there was an elevated risk of GG genotype (OR = 2.25, p = 0.01) in HCC patients compared to healthy controls. For rs17147230, T allele (OR = 1.31, p = 0.03) and TT genotype (OR = 1.83, p = 0.02) had elevated risks in HCC patients compared to healthy controls. Conclusions: The present meta-analysis confirmed that there was an elevated risk of the AA and GA genotypes of rs1800797 polymorphism and the GG genotype of rs2069837, and the T allele and TT genotype of rs17147230 in HCC.en_US
dc.identifier.doi10.5114/ceh.2020.102171
dc.identifier.endpage366en_US
dc.identifier.issn2392-1099
dc.identifier.issn2449-8238
dc.identifier.issue4en_US
dc.identifier.pmid33511285en_US
dc.identifier.scopus2-s2.0-85100023058en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage359en_US
dc.identifier.urihttps://doi.org/10.5114/ceh.2020.102171
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16640
dc.identifier.volume6en_US
dc.identifier.wosWOS:000615582500011en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofClinical And Experimental Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPolymorphismen_US
dc.subjectInterleukin 6en_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectHepatitisen_US
dc.subjectCirrhosisen_US
dc.titleAssociation between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu